Isogenica, which has its research facility in Cambridge, has entered into an agreement with Pfizer in which Isogenica’s CIS display technology will be evaluated by Pfizer for its ability to generate therapeutic peptide candidates. Financial terms of the agreement were not disclosed. "We look forward to building a strong and fruitful relationship with Pfizer and in assisting them with their therapeutic discovery activities" said Dr. Kevin FitzGerald, Isogenica's CEO.
Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides, polypeptides and antibodies that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.
"We believe that CIS display technology provides a powerful new approach for the discovery of peptides, antibodies and proteins for therapeutic and other in vivo applications"